Gap finder
Search review questions
Each row is one question a systematic review asked: who, what, compared with what, and which outcome, with the effect it found and how certain that is. Words match anywhere in the field.
15,213 questions in 2,394 reviews
current versionsNo studies 15,213 · 100%Ungraded 0 · 0%Very low 0 · 0%Low 0 · 0%Moderate 0 · 0%High 0 · 0%
Ungraded means an effect was reported without a GRADE rating; it is not a gap. No studies means the review found nothing to answer the question. The six categories are a display order, not a score.
| Question | Effect | Evidence | Status / GRADE |
|---|---|---|---|
Low glycaemic index (GI) or glycaemic load (GL) diets vs higher GI or GL diets All‐cause mortality · people with overweight or obesity Low glycaemic index or low glycaemic load diets for people with overweight or obesity (2023) · Cochrane | no estimate extracted | NR | No studies |
Low glycaemic index (GI) or low glycaemic load (GL) diets vs any other diet Health‐related quality of life · people with obesity or overweight Low glycaemic index or low glycaemic load diets for people with overweight or obesity (2023) · Cochrane | no estimate extracted | NR | No studies |
Topical aminocaproic acid vs placebo Long‐term visual acuity 20/40 or better > 2 months after treatment · people with traumatic hyphema Medical interventions for traumatic hyphema (2023) · Cochrane | no estimate extracted | NR | No studies |
Topical aminocaproic acid vs placebo Final visual acuity 20/40 or better at resolution of hyphema · people with traumatic hyphema Medical interventions for traumatic hyphema (2023) · Cochrane | no estimate extracted | NR | No studies |
Topical aminocaproic acid vs placebo Adverse effects: systemic hypotension · people with traumatic hyphema Medical interventions for traumatic hyphema (2023) · Cochrane | no estimate extracted | NR | No studies |
Systemic tranexamic acid vs control Medium‐term visual acuity 20/40 or better > 2 weeks and ≤ 2 months after treatment · people with traumatic hyphema Medical interventions for traumatic hyphema (2023) · Cochrane | no estimate extracted | NR | No studies |
Systemic tranexamic acid vs control Long‐term visual acuity 20/40 or better > 2 months after treatment · people with traumatic hyphema Medical interventions for traumatic hyphema (2023) · Cochrane | no estimate extracted | NR | No studies |
Systemic tranexamic acid vs control Final visual acuity 20/40 or better at resolution of hyphema · people with traumatic hyphema Medical interventions for traumatic hyphema (2023) · Cochrane | no estimate extracted | NR | No studies |
Systemic aminocaproic acid vs placebo Medium‐term visual acuity 20/40 or better > 2 weeks and ≤ 2 months after treatment · people with traumatic hyphema Medical interventions for traumatic hyphema (2023) · Cochrane | no estimate extracted | NR | No studies |
Systemic tranexamic acid vs control Adverse effects: nausea · people with traumatic hyphema Medical interventions for traumatic hyphema (2023) · Cochrane | no estimate extracted | NR | No studies |
Topical aminocaproic acid vs placebo Medium‐term visual acuity 20/40 or better > 2 weeks and ≤ 2 months after treatment · people with traumatic hyphema Medical interventions for traumatic hyphema (2023) · Cochrane | no estimate extracted | NR | No studies |
Probiotics vs control Neurodevelopmental impairment (18 months to 3 years) · extremely preterm or extremely low birth weight infants Probiotics to prevent necrotising enterocolitis in very preterm or very low birth weight infants (2023) · Cochrane | no estimate extracted | NR | No studies |
Summary of findings table ‐ Platelet transfusion vs open control Quality of life ‐ not reported · adults with acute spontaneous intracerebral haemorrhage associated with antiplatelet drug use Haemostatic therapies for stroke due to acute, spontaneous intracerebral haemorrhage (2023) · Cochrane | no estimate extracted | NR | No studies |
Summary of findings table ‐ Platelet transfusion vs open control Mood ‐ not reported · adults with acute spontaneous intracerebral haemorrhage associated with antiplatelet drug use Haemostatic therapies for stroke due to acute, spontaneous intracerebral haemorrhage (2023) · Cochrane | no estimate extracted | NR | No studies |
Summary of findings table ‐ Platelet transfusion vs open control Cognitive function ‐ not reported · adults with acute spontaneous intracerebral haemorrhage associated with antiplatelet drug use Haemostatic therapies for stroke due to acute, spontaneous intracerebral haemorrhage (2023) · Cochrane | no estimate extracted | NR | No studies |
Summary of findings table ‐ Prothrombin complex concentrates vs fresh frozen plasma Quality of life ‐ not reported · adults with acute spontaneous intracerebral haemorrhage associated with anticoagulant drug use Haemostatic therapies for stroke due to acute, spontaneous intracerebral haemorrhage (2023) · Cochrane | no estimate extracted | NR | No studies |
Summary of findings table ‐ Prothrombin complex concentrates vs fresh frozen plasma Mood ‐ not reported · adults with acute spontaneous intracerebral haemorrhage associated with anticoagulant drug use Haemostatic therapies for stroke due to acute, spontaneous intracerebral haemorrhage (2023) · Cochrane | no estimate extracted | NR | No studies |
Summary of findings table ‐ Prothrombin complex concentrates vs fresh frozen plasma Cognitive function ‐ not reported · adults with acute spontaneous intracerebral haemorrhage associated with anticoagulant drug use Haemostatic therapies for stroke due to acute, spontaneous intracerebral haemorrhage (2023) · Cochrane | no estimate extracted | NR | No studies |
Summary of findings table ‐ Recombinant activated factor VII vs placebo/open control Quality of life ‐ not reported · adults with acute spontaneous intracerebral haemorrhage Haemostatic therapies for stroke due to acute, spontaneous intracerebral haemorrhage (2023) · Cochrane | no estimate extracted | NR | No studies |
Summary of findings table ‐ Recombinant activated factor VII vs placebo/open control Mood ‐ not reported · adults with acute spontaneous intracerebral haemorrhage Haemostatic therapies for stroke due to acute, spontaneous intracerebral haemorrhage (2023) · Cochrane | no estimate extracted | NR | No studies |
Summary of findings table ‐ Recombinant activated factor VII vs placebo/open control Cognitive function ‐ not reported · adults with acute spontaneous intracerebral haemorrhage Haemostatic therapies for stroke due to acute, spontaneous intracerebral haemorrhage (2023) · Cochrane | no estimate extracted | NR | No studies |
Prostaglandin vs placebo or standard care Health‐related quality of life · adult liver transplanted recipients Prostaglandins for adult liver transplanted recipients (2023) · Cochrane | no estimate extracted | NR | No studies |
Cytisine vs varenicline Neuropsychiatric SAEs · people who smoke tobacco Nicotine receptor partial agonists for smoking cessation (2023) · Cochrane | no estimate extracted | NR | No studies |
Cytisine vs varenicline Cardiac SAEs · people who smoke tobacco Nicotine receptor partial agonists for smoking cessation (2023) · Cochrane | no estimate extracted | NR | No studies |
Cytisine vs nicotine replacement therapy Neuropsychiatric SAEs · people who smoke tobacco Nicotine receptor partial agonists for smoking cessation (2023) · Cochrane | no estimate extracted | NR | No studies |
Cytisine vs nicotine replacement therapy Cardiac SAEs · people who smoke tobacco Nicotine receptor partial agonists for smoking cessation (2023) · Cochrane | no estimate extracted | NR | No studies |
Cytisine vs placebo or no medication Neuropsychiatric SAEs (cytisine vs placebo or no medication) · people who smoke tobacco Nicotine receptor partial agonists for smoking cessation (2023) · Cochrane | no estimate extracted | NR | No studies |
Cytisine vs placebo or no medication Cardiac SAEs (cytisine vs placebo or no medication) · people who smoke tobacco Nicotine receptor partial agonists for smoking cessation (2023) · Cochrane | no estimate extracted | NR | No studies |
Medically assisted hydration vs standard care Quality of life · adults aged 18 years and older receiving palliative care Medically assisted hydration for adults receiving palliative care (2023) · Cochrane | no estimate extracted | NR | No studies |
Botulinum toxin vs surgery Serious adverse events at 6 or 12 months · adults and children with strabismus Botulinum toxin for the treatment of strabismus (2023) · Cochrane | no estimate extracted | NR | No studies |
Botulinum toxin vs surgery Quality of life, as measured by validated instruments · adults and children with strabismus Botulinum toxin for the treatment of strabismus (2023) · Cochrane | no estimate extracted | NR | No studies |
Summary of findings 2: PLD alone vs other conventional chemotherapy Quality of life · adult women with recurrent platinum‐resistant EOC Pegylated liposomal doxorubicin for relapsed epithelial ovarian cancer (2023) · Cochrane | no estimate extracted | NR | No studies |
Summary of findings 3: PLD with chemotherapy vs PLD alone Quality of life · adult women with recurrent platinum‐resistant epithelial ovarian cancer Pegylated liposomal doxorubicin for relapsed epithelial ovarian cancer (2023) · Cochrane | no estimate extracted | NR | No studies |
High vs low dose pegylated interferon alpha‐2a or alpha‐2b Death · patients on HD with HCV infection Interventions for dialysis patients with hepatitis C virus (HCV) infection (2023) · Cochrane | no estimate extracted | NR | No studies |
High vs low dose pegylated interferon alpha‐2a or alpha‐2b End‐of‐treatment response · patients on HD with HCV infection Interventions for dialysis patients with hepatitis C virus (HCV) infection (2023) · Cochrane | no estimate extracted | NR | No studies |
High vs low dose pegylated interferon alpha‐2a or alpha‐2b Treatment discontinuation · patients on HD with HCV infection Interventions for dialysis patients with hepatitis C virus (HCV) infection (2023) · Cochrane | no estimate extracted | NR | No studies |
High vs low dose pegylated interferon alpha‐2a or alpha‐2b Adverse events · patients on HD with HCV infection Interventions for dialysis patients with hepatitis C virus (HCV) infection (2023) · Cochrane | no estimate extracted | NR | No studies |
High vs low dose pegylated interferon alpha‐2a or alpha‐2b Serious adverse events · patients on HD with HCV infection Interventions for dialysis patients with hepatitis C virus (HCV) infection (2023) · Cochrane | no estimate extracted | NR | No studies |
Standard interferon plus ribavirin vs standard interferon alone Death · patients on HD with HCV infection Interventions for dialysis patients with hepatitis C virus (HCV) infection (2023) · Cochrane | no estimate extracted | NR | No studies |
Standard interferon plus ribavirin vs standard interferon alone Relapse(recurrence after stopping) · patients on HD with HCV infection Interventions for dialysis patients with hepatitis C virus (HCV) infection (2023) · Cochrane | no estimate extracted | NR | No studies |
Standard interferon plus ribavirin vs standard interferon alone End‐of‐treatment response · patients on HD with HCV infection Interventions for dialysis patients with hepatitis C virus (HCV) infection (2023) · Cochrane | no estimate extracted | NR | No studies |
Standard interferon plus ribavirin vs standard interferon alone Sustained virological response · patients on HD with HCV infection Interventions for dialysis patients with hepatitis C virus (HCV) infection (2023) · Cochrane | no estimate extracted | NR | No studies |
Standard interferon plus ribavirin vs standard interferon alone Adverse events · patients on HD with HCV infection Interventions for dialysis patients with hepatitis C virus (HCV) infection (2023) · Cochrane | no estimate extracted | NR | No studies |
Pegylated interferon plus ribavirin vs pegylated interferon alone Death · HD patients with HCV infection Interventions for dialysis patients with hepatitis C virus (HCV) infection (2023) · Cochrane | no estimate extracted | NR | No studies |
Direct antivirals (grazoprevir and elbasvir) vs placebo Death · HD patients with HCV infection Interventions for dialysis patients with hepatitis C virus (HCV) infection (2023) · Cochrane | no estimate extracted | NR | No studies |
Direct antivirals (grazoprevir and elbasvir) vs placebo Relapse · HD patients with HCV infection Interventions for dialysis patients with hepatitis C virus (HCV) infection (2023) · Cochrane | no estimate extracted | NR | No studies |
Direct antivirals (grazoprevir and elbasvir) vs placebo Sustained virological response · HD patients with HCV infection Interventions for dialysis patients with hepatitis C virus (HCV) infection (2023) · Cochrane | no estimate extracted | NR | No studies |
Direct antivirals (grazoprevir and elbasvir) vs placebo Treatment discontinuation · HD patients with HCV infection Interventions for dialysis patients with hepatitis C virus (HCV) infection (2023) · Cochrane | no estimate extracted | NR | No studies |
Direct antivirals (grazoprevir and elbasvir) vs placebo Adverse events · HD patients with HCV infection Interventions for dialysis patients with hepatitis C virus (HCV) infection (2023) · Cochrane | no estimate extracted | NR | No studies |
Pegylated interferon + ribavirin (24 weeks) + initial telepravir (12 weeks) vs pegylated interferon (48 weeks) + initial telepravir (12 weeks) + initial low dose ribavirin (12 + 36 weeks) Death · HD patients with HCV infection Interventions for dialysis patients with hepatitis C virus (HCV) infection (2023) · Cochrane | no estimate extracted | NR | No studies |